On July 17, 2019 Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported it will host a conference call and webcast with a question-and-answer session on Monday, July 22, 2019 at 5:30 a.m. PDT/ 8:30 a.m. EDT to review data from an investigator-sponsored Phase 1/2 clinical trial with its MultiTAA therapy in patients with pancreatic adenocarcinoma (Press release, Marker Therapeutics, JUL 17, 2019, https://www.prnewswire.com/news-releases/marker-therapeutics-to-host-conference-call-and-webcast-to-review-interim-results-from-phase-12-clinical-trial-with-its-multitaa-t-cell-therapy-in-patients-with-pancreatic-adenocarcinoma-300886184.html [SID1234537582]). The data will also be reviewed in plenary and poster sessions on Saturday, July 20 at a cell therapy conference hosted by the American Association for Cancer Research (AACR) (Free AACR Whitepaper) in San Francisco by Brandon G. Smaglo, M.D., FACP, Assistant Professor, Medical Director of Hematology/Oncology at the Baylor College of Medicine, Houston, Texas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live conference call and webcast will be accessible in the Investors section of the Company’s website at www.markertherapeutics.com. The archived webcast will be available for replay on the Marker website following the event.